Search

Displaying results 2001 - 2010 of 6951 in total
  1. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil. … [A258318] The FDA approved the use of vardenafil for the treatment of erectile dysfunction in 2003.

  2. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    Casirivimab is a monoclonal antibody combined with [Imdevimab] in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. … They are reserved for Emergency Use Authorization (EUA) only.[L23524] In November 2021, the same indication was approved by the EMA.

    Categories: Antiinfectives for Systemic Use, Approved Treatments for COVID-19
  3. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia.

    Categories: Adenosine A2 Receptor Antagonists, Purinergic P1 Receptor Antagonists
  4. Drug

    Oteseconazole

    go.drugbank.com/drugs/DB13055
    ApprovedInvestigational

    [L41635] Unlike previous-generation azole antifungals, oteseconazole has a high selectivity for CYP51 and little interaction with human cytochrome P450s.

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for

  6. Drug

    Malathion

    go.drugbank.com/drugs/DB00772
    Approved

    Malathion is a parasympathomimetic organophosphate compound that is used as an insecticide for the treatment of head lice.

  7. Drug

    Donidalorsen

    go.drugbank.com/drugs/DB18751
    ApprovedInvestigational

    [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]

  8. Drug

    Telaprevir

    go.drugbank.com/drugs/DB05521
    ApprovedWithdrawn

    Telaprevir was available as a fixed dose product (tradename Incivek) used for the treatment of chronic Hepatitis C. … The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [A19593].

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Delavirdine

    go.drugbank.com/drugs/DB00705
    ApprovedInvestigationalWithdrawn

    A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    Ciclopirox

    go.drugbank.com/drugs/DB01188
    ApprovedInvestigational

    Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses.

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use